2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 | 1160994-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃[2,3-d]嘧啶
• 中文名称: 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶
• 英文名称: 2,4-Dichloro-5-methylfuro[2,3-d]pyrimidine
• CAS: 1160994-79-5
• 化学式: C₇H₄Cl₂N₂O
• 分子量: 203.028
• InChiKey: OCTXLKXOUFKWPY-UHFFFAOYSA-N

物化性质

• 沸点：
  251.7±22.0 °C(Predicted)
• 密度：
  1.526±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 在 ammonium hydroxide 、 锌 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 [(7R)-4-(4-amino-5-methylfuro[2,3-d]pyrimidin-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
  参考文献：
  名称：

  Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis

  摘要：

  Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. Previously we have disclosed several compounds in the diazepane amide DORA series with excellent potency and both preclinical and clinical sleep efficacy. Additional SAR studies in this series were enabled by the expansion of the acetonitrile-assisted, diphosgene-mediated 2,4-dichloropyrimidine synthesis to novel substrates providing an array of Western heterocycles. These heterocycles were utilized to synthesize analogs in short order with high levels of potency on orexin 1 and orexin 2 receptors as well as in vivo sleep efficacy in the rat. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.052
• 作为产物：
  描述：

  2-氨基-4-甲基-3-呋喃甲酰腈 、 氯甲酸三氯甲酯 以 乙腈 为溶剂， 生成 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶
  参考文献：
  名称：

  Substituted diazepan orexin receptor antagonists

  摘要：

  本发明涉及替代二氮杂环丙烷化合物，其为促进睡眠蛋白受体的拮抗剂，可用于治疗或预防神经和精神疾病，以及涉及促进睡眠蛋白受体的疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在预防或治疗涉及促进睡眠蛋白受体的疾病中的用途。

  公开号：

  US20080132490A1

文献信息

• Substituted diazepan orexin receptor antagonists
  申请人：Bergman Jeffrey M.

  公开号：US20080132490A1

  公开（公告）日：2008-06-05

  The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及替代二氮杂环丙烷化合物，其为促进睡眠蛋白受体的拮抗剂，可用于治疗或预防神经和精神疾病，以及涉及促进睡眠蛋白受体的疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在预防或治疗涉及促进睡眠蛋白受体的疾病中的用途。
• Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis
  作者：Anthony J. Roecker、Swati P. Mercer、C. Meacham Harrell、Susan L. Garson、Steven V. Fox、Anthony L. Gotter、Thomayant Prueksaritanont、Tamara D. Cabalu、Donghui Cui、Wei Lemaire、Christopher J. Winrow、John J. Renger、Paul J. Coleman

  DOI：10.1016/j.bmcl.2014.03.052

  日期：2014.5

  Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. Previously we have disclosed several compounds in the diazepane amide DORA series with excellent potency and both preclinical and clinical sleep efficacy. Additional SAR studies in this series were enabled by the expansion of the acetonitrile-assisted, diphosgene-mediated 2,4-dichloropyrimidine synthesis to novel substrates providing an array of Western heterocycles. These heterocycles were utilized to synthesize analogs in short order with high levels of potency on orexin 1 and orexin 2 receptors as well as in vivo sleep efficacy in the rat. (C) 2014 Elsevier Ltd. All rights reserved.